Table 3. Clinical performance of the cervical cancer screening tests using a CIN2+ threshold.

	VIA	DC	Xpert HPV	OncoE6
True positive	15	19	28	10
False positive	14	20	66	1
True negative	153	147	100	166
False negative	16	13	4	22
Sensitivity (95% CI)	48% (30-67%)	59% (41-76%)	88% (71-97%)	31% (16-50%)
Specificity (95% CI)	92% (86-95%)	88% (82-93%)	60% (52-68%)	99% (97-100%)
PPV (95% CI)	52% (33-71%)	49% (32-65%)	30% (21-40%)	91% (59-100%)
NPV (95% CI)	91% (85-95%)	92% (87-96%)	96% (90-99%)	88% (83-93%)
PLR (95% CI)	10 (4-25)	5 (3-8)	2 (2-3)	52 (7-394)
NLR (95% CI)	0.6 (0.4-0.8)	0.5 (0.3-0.7)	0.2 (0.1-0.5)	0.7 (0.5-0.9)
OR (95% CI)	10 (4-25)	11 (4-25)	11 (4-30)	76 (12-.)

VIA: visual inspection with acetic acid; DC: digital cervicography; 95% CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio; OR: odds ratio